Marius Miglinas

Summary

Affiliation: Vilnius university
Location: Vilnius, Lithuania
Summary:
Dr. Miglinas currently serves as a Vice President of Lithuanian Nephrology Dialysis and Transplant Association and as a President of Lithuanian Hypertension Society. He also takes a lead to Nephrology Center at the Vilnius University hospital, Vilnius University in Vilnius (Lithuania).

Dr. Miglinas received his medical degree from Vilnius University in Lithuania. He trained as an intern in Vilnius, and as an International Society of Nephrology Fellow at Glasgow University Western Infirmary in Scotland, U.K. Dr. Miglinas received the award of Matsumae International Foundation (Japan) to study uremic toxicity in chronic renal failure patients at the Nagoya University, Nagoya, Japan under guidance of prof. T.Niwa in 2002.
In 2007 he has been trained as an EDTA/ERA Fellow in Vienna university hospital (Austria) in the field of the kidney recipient waiting list management and approach to the sensitized kidney recipient. Dr. Miglinas has also been trained at the Transplant and Renal Education Center, Westmead hospital, Sydney (Australia) under guidance of prof. J. Chapman from 21-st of February 2013 to 19-th of April, 2013.

Dr. Miglinas research interests are renal biopsy and glomerular involvement in primary and secondary glomerular diseases, kidney involvement in arterial hypertension, management of hypertension in renal patients and diabetics, kidney transplantation, interventional nephrology and chronic kidney disease epidemiology. His expertise includes glomerular disease management, treatment of hypertension in chronic kidney disease and resistant hypertension work-up, dialysis-related complications and kidney transplant recipients
Grants:
1996, International Society of Nephrology
2002, Matsumae International Foundation
2007, EDTA/ERA
Publications:
1. Delayed graft function: risk factors and the effects of early function and graft survival. Transplant Proc. 2013 May;45(4):1363-7. doi: 10.1016/j.transproceed.2013.03.014. PMID:
2. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. PMID: [PubMed - indexed for MEDLINE]
3. The First ABO-Incompatible Kidney Transplantation in Lithuania and Baltic States. Therapeutic Apheresis and Dialysis. 2011, Vol. 15, no. 4 : ISFA Vienna 2011, 8th International Society for Apheresis Congress, 3rd Wiener Aphereseseminar; September 14

Publications

  1. doi request reprint Cardiorenal end points in a trial of aliskiren for type 2 diabetes
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 367:2204-13. 2012
  2. doi request reprint Delayed graft function: risk factors and the effects of early function and graft survival
    M Miglinas
    Vilnius University, Vilnius University Hospital, Santariskiu Klinikos, Vilnius, Lithuania
    Transplant Proc 45:1363-7. 2013

Detail Information

Publications2

  1. doi request reprint Cardiorenal end points in a trial of aliskiren for type 2 diabetes
    Hans Henrik Parving
    Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 367:2204-13. 2012
    ..This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both...
  2. doi request reprint Delayed graft function: risk factors and the effects of early function and graft survival
    M Miglinas
    Vilnius University, Vilnius University Hospital, Santariskiu Klinikos, Vilnius, Lithuania
    Transplant Proc 45:1363-7. 2013
    ..It affects 25% to 50% of recipients. In this study we identified risk factors for DGF and its impact on patient and graft survivals...